House Dust Mite Allergy Evidence-Based Management-Separating Truth from Fiction

Price: FREE for members, $25 non-members

Patients with house dust mite allergy and asthma comprise a major number of patients cared for by the allergist. This activity will review the latest published data on house dust mite management and break many of the myths of “what works best” for our patients. 

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring activity for a maximum of 1 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity was supported by an independent educational grant from ALK-Abelló, Inc.

Target Audience

Allergists, allied health and other allergy practitioners.

Learning Objectives

  1. Describe how effective indoor dust mite reduction is in improving allergy and asthma control
  2. Summarize the efficacy and value of pharmacologic agents in decreasing symptoms related to house dust mites
  3. Compare subcutaneous to sublingual tablet immunotherapy in relief of house dust mite allergy and asthma from the latest published data
  4. Be able to employ shared decision making for house dust mite immunotherapy in your practice setting
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

All identified conflicts of interest have been resolved.

Eli Meltzer, MD, FACAAI

ALK Consultant, Speaker Honorarium, Consulting fee
AstraZeneca Consultant Consulting fee
Boehringer-Ingelheim Consultant Consulting fee
GlaxoSmithKline Consultant Consulting fee

Glenmark: Consultant, Speaker; Consulting Fee,
Honorarium. GossamerBio: Consultant; Consulting Fee.
Merck: Consultant; Consulting Fee. Mylan: Consultant;
Consulting Fee. Regeneron/Sanofi: Consultant,
Speaker; Consulting Fee, Honorarium.

John Oppenheimer, MD, FACAAI

Teva Consultant, Consulting fee
DBV Technologies, Consultant, Consulting fee
GlaxoSmithKline, Consultant, Consulting fee
MedImmune Adjudication, Consulting fee
Sanofi Consultant, Consulting fee
Up to Date Reviewer, Honorarium
Medscape Senior Editor, Honorarium

Michael Blaiss, MD, FACAAI

ALK Consultant, Consulting fee
Boston Scientific Consultant, Consulting fee
Pfizer Consultant, Consulting fee
PMD Healthcare Consultant, Consulting fee
RX Bands Consultant, Consulting fee
Stallergenes Consultant, Consulting fee

Gerald Lee, MD FACAAI - Nothing to disclose

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance


Please login or create an account to take this course.